CA3125193A1 - Claudin18.2 binding moieties and uses thereof - Google Patents

Claudin18.2 binding moieties and uses thereof Download PDF

Info

Publication number
CA3125193A1
CA3125193A1 CA3125193A CA3125193A CA3125193A1 CA 3125193 A1 CA3125193 A1 CA 3125193A1 CA 3125193 A CA3125193 A CA 3125193A CA 3125193 A CA3125193 A CA 3125193A CA 3125193 A1 CA3125193 A1 CA 3125193A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
nos
acid sequences
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3125193A
Other languages
English (en)
French (fr)
Inventor
Liusong YIN
Tielin ZHOU
Zhuo FANG
Yong Liu
Qiuchuan ZHUANG
Bo Wu
Xiaohu FAN
Qingshan Zhang
Dan Zhao
Jie Mao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Jinsirui Science and Technology Biology Corp
Nanjing Legend Biotechnology Co Ltd
Original Assignee
Nanjing Jinsirui Science and Technology Biology Corp
Nanjing Legend Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Jinsirui Science and Technology Biology Corp, Nanjing Legend Biotechnology Co Ltd filed Critical Nanjing Jinsirui Science and Technology Biology Corp
Publication of CA3125193A1 publication Critical patent/CA3125193A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3125193A 2018-12-28 2019-12-27 Claudin18.2 binding moieties and uses thereof Pending CA3125193A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018125052 2018-12-28
CNPCT/CN2018/125052 2018-12-28
CNPCT/CN2019/095827 2019-07-12
CN2019095827 2019-07-12
PCT/CN2019/129017 WO2020135674A1 (en) 2018-12-28 2019-12-27 Claudin18.2 binding moieties and uses thereof

Publications (1)

Publication Number Publication Date
CA3125193A1 true CA3125193A1 (en) 2020-07-02

Family

ID=71127698

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3125193A Pending CA3125193A1 (en) 2018-12-28 2019-12-27 Claudin18.2 binding moieties and uses thereof

Country Status (12)

Country Link
US (1) US12258418B2 (cg-RX-API-DMAC7.html)
EP (1) EP3902839A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022515487A (cg-RX-API-DMAC7.html)
KR (1) KR20210110339A (cg-RX-API-DMAC7.html)
CN (1) CN113227146B (cg-RX-API-DMAC7.html)
AU (1) AU2019415848B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012608A2 (cg-RX-API-DMAC7.html)
CA (1) CA3125193A1 (cg-RX-API-DMAC7.html)
IL (1) IL284393A (cg-RX-API-DMAC7.html)
MX (1) MX2021007939A (cg-RX-API-DMAC7.html)
SG (1) SG11202106534RA (cg-RX-API-DMAC7.html)
WO (1) WO2020135674A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021023024A2 (pt) * 2019-05-16 2022-01-25 Qilu Pharmaceutical Co Ltd Anticorpo contra claudina 18a2 e uso do mesmo
AU2020378502A1 (en) 2019-11-05 2022-06-16 LaNova Medicines Limited Antibody-drug conjugates targeting claudin 18.2
CN114829408B (zh) 2019-12-20 2024-01-26 山东博安生物技术股份有限公司 用于免疫治疗的t细胞双特异性抗体生产中的优化抗cd3臂
CN113637082A (zh) * 2020-04-27 2021-11-12 启愈生物技术(上海)有限公司 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
CN115698072B (zh) 2020-07-01 2023-07-04 山东博安生物技术股份有限公司 抗gpc3抗体,抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体
CN111808194B (zh) * 2020-07-13 2021-04-20 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
WO2022063272A1 (en) * 2020-09-28 2022-03-31 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-claudin18 antibodies
TW202233248A (zh) 2020-11-08 2022-09-01 美商西健公司 組合療法
KR20230113578A (ko) * 2020-11-27 2023-07-31 선샤인 레이크 파르마 컴퍼니 리미티드 Cldn18.2 항체 및 그의 용도
CN114539402B (zh) * 2020-11-27 2025-06-13 南京北恒生物科技有限公司 靶向Claudin18.2的抗体及其用途
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
KR20230124037A (ko) 2020-12-23 2023-08-24 소티오 바이오테크 에이.에스. 종양 특이적 claudin 18.2 항체-약물 접합체
CN113321730B (zh) * 2021-01-11 2023-10-10 上海莱馥医疗科技有限公司 Cldn18.2抗体及其应用
CN116940598A (zh) * 2021-02-08 2023-10-24 山东博安生物技术股份有限公司 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体
CN115109154A (zh) * 2021-03-17 2022-09-27 三优生物医药(上海)有限公司 一种靶向cldn18.2的抗体或其抗原结合片段及其应用
WO2022206975A1 (zh) * 2021-04-02 2022-10-06 原启生物科技(上海)有限责任公司 Cldn18.2抗原结合蛋白及其用途
EP4335873A4 (en) * 2021-05-08 2025-03-19 RemeGen Co., Ltd. ANTI-CLAUDIN 18.2 ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF
WO2023167564A1 (ko) 2022-03-04 2023-09-07 앱티스 주식회사 티올 반응성 에디티브를 이용한 항체-약물 컨쥬게이트의 제조 수율을 높이는 방법
AU2023371764A1 (en) 2022-11-01 2025-05-15 AbTis Co., Ltd. Compound comprising fc-binding unit, and conjugate prepared using same
EP4653017A1 (en) 2023-01-18 2025-11-26 Tyligand Bioscience (Shanghai) Limited Antibody-drug conjugate and use thereof
CN116284224B (zh) * 2023-05-12 2023-07-25 中国农业大学 一种结合Claudin 18.2的环肽及其应用
WO2025038602A1 (en) * 2023-08-14 2025-02-20 Ginkgo Bioworks, Inc. Immune cell stimulatory sequences
CN121969385A (zh) 2023-09-11 2026-05-01 丹娜-法伯癌症研究院 含有il-2变体以增强car t细胞的功能性的car-衔接子
WO2025072299A1 (en) * 2023-09-25 2025-04-03 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技(上海)有限公司 一种抗体偶联药物及其用途
CN120829517A (zh) * 2024-04-22 2025-10-24 鲁南新时代生物技术有限公司 抗cldn18.2/cd3双特异性抗体及用途
WO2025251228A1 (en) 2024-06-05 2025-12-11 Nuwacell Biotechnologies Co., Ltd. Cldn18.2-targeting chimeric antigen receptor and engineered cell

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN120329449A (zh) * 2014-07-17 2025-07-18 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药(上海)有限公司 抗密蛋白18a2的抗体及其应用
MX2020009326A (es) * 2018-03-08 2020-10-08 Phanes Therapeutics Inc Anticuerpos anti-claudina 18.2 y usos de los mismos.
CN116178554B (zh) * 2018-05-18 2025-09-09 礼新医药科技(上海)有限公司 抗密蛋白18.2抗体及其用途
JP7840511B2 (ja) * 2019-02-01 2026-04-06 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 抗クローディン18抗体及びそれらの使用の方法
CN114630840B (zh) * 2019-08-20 2024-08-02 苏州创胜医药集团有限公司 新型抗cldn18.2抗体

Also Published As

Publication number Publication date
MX2021007939A (es) 2021-10-22
AU2019415848A8 (en) 2021-09-02
BR112021012608A2 (pt) 2021-09-08
SG11202106534RA (en) 2021-07-29
WO2020135674A1 (en) 2020-07-02
EP3902839A1 (en) 2021-11-03
AU2019415848A1 (en) 2021-08-19
KR20210110339A (ko) 2021-09-07
CN113227146A (zh) 2021-08-06
US20220073643A1 (en) 2022-03-10
US12258418B2 (en) 2025-03-25
JP2022515487A (ja) 2022-02-18
JP7724332B2 (ja) 2025-08-15
JP2024125370A (ja) 2024-09-18
AU2019415848B2 (en) 2026-06-25
CN113227146B (zh) 2024-03-01
IL284393A (en) 2021-08-31
EP3902839A4 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
JP7724332B2 (ja) クローディン18.2結合部分およびその利用
CA3230426A1 (en) Bispecific binding proteins that bind cd137 and a tumor associated antigen
JP2022519118A (ja) 抗クローディン18抗体及びそれらの使用の方法
JP7368453B2 (ja) Pd-1およびlag-3に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質
BRPI0812913B1 (pt) Anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano PD-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos
CA3193584A1 (en) Nectin-4 antibodies and uses thereof
WO2023151693A1 (zh) 包含抗tigit抗体和抗pd-1-抗vegfa双特异性抗体的药物组合物及用途
EP3041868A2 (en) Cd70-binding peptides and method, process and use relating thereto
CN114981301B (zh) Pd1和vegfr2双结合剂
CN116390953A (zh) 靶向人密蛋白18.2的抗体及其用途
WO2023138579A1 (zh) 抗b7-h7抗体或其抗原结合片段及制备方法和应用
KR20250035542A (ko) 항-cldn18.2 항체 및 이의 약제학적 조성물 및 용도
CN119278213A (zh) 针对ctla-4的抗体及其使用方法
CN110950959B (zh) 靶向EpCAM的抗体及其制备和应用
AU2024267522A1 (en) Trop2 antibodies
US12606635B2 (en) Glypican-2-binding moieties, chimeric antigen receptors and uses thereof
EA047760B1 (ru) Группы, связывающие клаудин 18.2, и их использование
WO2026022767A1 (ko) B7-h3을 표적하는 항체, 및 이를 포함하는 키메라 항원 수용체
HK40089230A (en) Pharmaceutical composition and use
WO2022262749A1 (zh) 靶向pd1和/或ox40的特异性结合蛋白
HK40108283A (en) Anti-b7-h4/anti-4-1bb bispecific antibodies and use thereof
CN118234511A (zh) 与cd137和肿瘤相关抗原结合的双特异性结合蛋白
HK40033623B (en) Antibody binding to pd-1
HK40044020A (en) High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220831

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241129

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241212

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241212

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241212

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250325

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250402

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250716

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250716

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251217

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260605

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260605

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20260612

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260626

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260626